A study from the University of Maryland, Baltimore County (UMBC), published in Nature Communications, reveals how ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic ...
In a study published in Science Translational Medicine, researchers at Cedars-Sinai report that an experimental drug called TY1 helped damaged hearts heal in laboratory animals. It did not thin blood ...
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
A research team compared cassava—naturally adapted to tropical climates—with heat-sensitive potato to understand how each ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...
Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback